ArticleJAMA network open2023
Unreported SARS-CoV-2 Home Testing and Test Positivity.
Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- Evaluation of Kindergarten Through Grade 12 All-Cause Absenteeism Data as an Indicator and Predictor of Respiratory Disease, 2018-2022.Public health reports (Washington, D.C. : 1974) · 2025Article
- Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality.Scientific reports · 2025Article
- The Shift to Over-the-Counter Diagnostic Testing After RADx: Clinical, Regulatory, and Societal Implications.IEEE open journal of engineering in medicine and biology · 2025Article
- Epidemiological model can forecast COVID-19 outbreaks from wastewater-based surveillance in rural communities.Water research · 2025Article
- Article
- Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.Lancet regional health. Americas · 2024Article
- COVID-19 Linked Social Stigma Among Arab Survivors: A Cross-Sectional Experiences from the Active Phase of the Pandemic.Journal of multidisciplinary healthcare · 2024Article
- Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System.Infectious diseases and therapy · 2024Article
- "Boosting" Surveillance for a More Impactful Public Health Response During Protracted and Evolving Infectious Disease Threats: Insights From the COVID-19 Pandemic.Health security · 2023Article
- Changing patterns of infectious diseases in children during the COVID-19 pandemic.Frontiers in cellular and infection microbiology · 2023Review
- Seasonality of COVID-19 incidence in the United States.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.